AI Article Synopsis
- Abemaciclib and olaparib have been approved for use in the adjuvant treatment of early-stage breast cancer, marking a significant shift in treatment standards.
- Recent studies, including the NATALEE trial, are showing promising results by exploring further developments in adjuvant therapies.
- Ongoing clinical research is also examining established metastatic treatments, such as trastuzumab deruxtecan and sacituzumab govitecan, for potential use in earlier-stage cancer settings.
Article Abstract
With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study. Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan. In this review paper, we summarize and place in context the latest developments over the past months.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617391 | PMC |
| http://dx.doi.org/10.1055/a-2074-0551 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!